For the quarter ending 2025-02-23, LFCR made $35,154K in revenue. -$17,379K in net income. Net profit margin of -49.44%.
| Income Statement | 2025-02-23 | 2024-11-24 | ||
|---|---|---|---|---|
| Revenues | 35,154 | 32,564 | ||
| Cost of goods sold | 25,309 | 21,480 | ||
| Gross profit | 9,845 | 11,084 | ||
| Restructuring costs (recovery) | -115 | - | ||
| Selling, general, and administrative expenses | 10,093 | 11,119 | ||
| Research and development expenses | 2,045 | 1,924 | ||
| Total operating costs and expenses | - | 13,043 | ||
| Loss on sale or disposal of assets, net of portion classified as cost of sales | -6,851 | - | ||
| Interest expense, net | - | 5,465 | ||
| Operating loss | -9,029 | -1,959 | ||
| Other income (expense), net | 333 | -304 | ||
| Interest expense, net | -5,481 | - | ||
| Change in fair value of debt derivative liability, related party | -600 | 1,200 | ||
| (loss) income from continuing operations before income taxes | -14,777 | -6,528 | ||
| Income tax benefit (expense) | -8 | 43 | ||
| (loss) income from continuing operations | -14,769 | -6,571 | ||
| Net (loss) income | -14,769 | -6,571 | ||
| Accretion of preferred stock to redemption value | 144 | - | ||
| Fair value of conversion ratio improvement to preferred stockholders | - | 2,132 | ||
| Preferred stock dividends | 2,466 | - | ||
| (loss) income available to common stockholders | -17,379 | -8,703 | ||
| Basic eps | -0.47 | -0.25 | ||
| Diluted eps | -0.47 | -0.25 | ||
| Basic average shares | 37,020,570 | 34,360,657 | ||
| Diluted average shares | 37,020,570 | 34,360,657 | ||
LIFECORE BIOMEDICAL, INC. DE (LFCR)
LIFECORE BIOMEDICAL, INC. DE (LFCR)